esp | eng
R & D


mail Laboratorios SALVAT, S.A.

+34 933 946 400

R & D

INNOVATION

SALVAT bases its business growth on the development of innovative medicines, whether through projects stemming from the company’s in-house R&D, or by setting up links and partnerships with both public and private external research groups and collaboration agreements with other companies.

SALVAT’s Research Centre in Esplugues de Llobregat boasts not only the most advanced technology but also a highly qualified, multidisciplinary team of researchers. It has a flexible organisational system that covers Medicinal Chemistry, Bioanalysis, Biochemistry and Cellular Biology, Microbiology, Pharmacology and Pharmaceutical Development laboratories. The rest of the Centre includes the Clinical Research, Patents and Technical Documentation, Quality Assurance and Regulatory Affairs Departments.

Between 15% and 20% of SALVAT’s turnover and more than 15% of its personnel are dedicated to research projects. The company has received the “Very Good” classification from Plan Profarma. This is a joint programme set up by the Ministry of Industry, Tourism and Trade and the Ministry of Health, Social Services and Equality with the aim of encouraging the modernisation of the pharmaceutical sector and supporting activities such as R&D that bring greater added value, which is essential for the sector. The programme awards the classifications of “Acceptable”, “Good”, “Very Good” or “Excellent” on the basis of scientific, economic and industrial aspects.

SALVAT’s strategic research is focused on four therapeutic areas: gastroenterology, urology, ENT and ophthalmology. The range of different products developed by SALVAT includes new medicinal products, medical devices, antiseptics, nutraceuticals and probiotics, with the common goal of providing innovative products which help to improve people’s quality of life.

ENT

With vast experience in developing products for otitis, SALVAT is currently extending its reach in this area by investigating new therapeutic agents and pharmaceutical developments for the treatment of incurable hearing disorders such as acute hypoacusis, otitis media, presbycusis, etc. In line with the strategy of active collaboration with external groups of excellence, SALVAT has set up a Sponsored Chair with the Universidad Autónoma de Madrid (UAM) to promote and develop research activities in otology. (http://www.fuam.es/index.php/uam-laboratorios-salvat)

Ophthalmology

SALVAT has burst onto the ophthalmology scene with the aim of providing doctors and patients with solutions for their needs in the area of vision problems. The company has developed a plan which ranges from new therapeutic targets for treating glaucoma, medical devices and nutraceuticals with a solid scientific base, to equipment for measuring the health of the cornea. SALVAT is participating in the creation of the Cluster de Oftalmología [Ophthalmology Cluster], inspired by the Instituto de Oftalmobiología Aplicada de la Universidad de Valladolid (IOBA) [University of Valladolid Institute of Applied Ophthalmology] (http://www.ioba.med.uva.es/index_00.php?op=nov.det&idNot=fBzzpLrBBl), and has established collaboration agreements with a number of different groups to promote the development of new ideas.

Gastroenterology

Introducing intestinal microbiota in different diseases is one of the most recent advances in the field of gastroenterology. SALVAT is collaborating with renowned centres such as the INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS (IATA-CSIC) [Institute of Agrochemistry and Food Technology] in Valencia in order to discover new probiotics with therapeutic effect in different gastrointestinal and metabolic diseases. Another recent collaboration has been taken up with the Universidad Católica San Antonio in Murcia to work on new nutraceuticals projects.

SALVAT Biotech

SALVAT Biotech was founded in 2004 with the aim of concentrating all the SALVAT group’s activities in the field of Biotechnology applied to human health. SALVAT Biotech runs a number of different research projects.

SALVAT Biotech’s main activities have been established in the following areas:

Molecular diagnosis

Regenerative medicine

New forms of drug delivery

SALVAT Biotech invests in external biotechnology projects in the field of human health in the search for synergy possibilities with the rest of its portfolio and objectives.

SALVAT Biotech also acquires shares in new biotechnology companies that work in human health. In some instances, SALVAT Biotech acts purely as long-term shareholder, whereas in others it also provides its know-how in terms of project management. 

Current projects:

Advanced therapies

New cell-therapy medication for bone regeneration in complicated bone fractures or bone defects for which, at present, there is no treatment. Currently in the preclinical development phase, the plan is to start clinical trials in the first half of 2013. SALVAT is collaborating with HISTOCELL, a biotechnology company that works in tissue engineering and cell therapy.

Predictive medicine

In collaboration with the company Proteomika, SALVAT is developing a new kit for the early detection of bladder cancer and lung cancer from urine and plasma samples, respectively.

 



Laboratorios SALVAT S.A.
C\ Gall, 30-36 08950 - Esplugues de Llobregat - Barcelona España Tel. +34 933 946 400 Fax. +34 934 732 292 salvat@svt.com
1200 Brickell Avenue, Suite 1950, Miami, FL 33131 (US) Tel. +1 786-528-5273 salvatusa@svt.com